Trending Stock News

Shell Asset Management Co Has Decreased Its Huntington Ingalls Inds (HII) Position; Sangamo Therapeutics (SGMO) Shorts Increased By 6.56%

Sangamo Therapeutics Incorporated (NASDAQ:SGMO) had an increase of 6.56% in short interest. SGMO’s SI was 8.39M shares in February as released by FINRA. Its up 6.56% from 7.87M shares previously. With 1.29M avg volume, 7 days are for Sangamo Therapeutics Incorporated (NASDAQ:SGMO)’s short sellers to cover SGMO’s short positions. The SI to Sangamo Therapeutics Incorporated’s float is 12.69%. The stock increased 9.73% or $2 during the last trading session, reaching $22.55. About 2.17 million shares traded or 38.59% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 15, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Shell Asset Management Co decreased Huntington Ingalls Inds Inc (HII) stake by 14.19% reported in 2017Q3 SEC filing. Shell Asset Management Co sold 3,065 shares as Huntington Ingalls Inds Inc (HII)’s stock declined 7.75%. The Shell Asset Management Co holds 18,538 shares with $4.20 million value, down from 21,603 last quarter. Huntington Ingalls Inds Inc now has $10.93 billion valuation. The stock increased 1.66% or $3.94 during the last trading session, reaching $241.4. About 492,109 shares traded. Huntington Ingalls Industries, Inc. (NYSE:HII) has risen 26.91% since February 15, 2017 and is uptrending. It has outperformed by 10.21% the S&P500.

Investors sentiment decreased to 0.82 in Q3 2017. Its down 0.14, from 0.96 in 2017Q2. It turned negative, as 31 investors sold HII shares while 150 reduced holdings. 41 funds opened positions while 108 raised stakes. 37.19 million shares or 3.38% less from 38.49 million shares in 2017Q2 were reported. Dubuque Bancorporation holds 133 shares. Glg Ltd Partnership reported 1,500 shares or 0.02% of all its holdings. Prudential Fincl Incorporated reported 553,057 shares. Bank & Trust owns 1,286 shares. Bank & Trust Of Ny Mellon holds 626,959 shares. Hbk Investments Ltd Partnership accumulated 0.01% or 5,799 shares. Smithfield stated it has 0% in Huntington Ingalls Industries, Inc. (NYSE:HII). Lpl Fincl Llc has 3,406 shares. Loomis Sayles Lp invested in 0% or 96 shares. Franklin Res invested in 0.05% or 427,484 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt has 6,624 shares for 0.02% of their portfolio. Scout Investments, Missouri-based fund reported 114,094 shares. Advisory Services Net Limited Liability has 250 shares for 0.01% of their portfolio. Usa Financial Portformulas Corporation has invested 0.27% of its portfolio in Huntington Ingalls Industries, Inc. (NYSE:HII). Fuller & Thaler Asset Mgmt accumulated 0% or 500 shares.

Shell Asset Management Co increased Signature Bk New York N Y (NASDAQ:SBNY) stake by 8,745 shares to 34,538 valued at $4.42M in 2017Q3. It also upped Marten Trans Ltd (NASDAQ:MRTN) stake by 21,274 shares and now owns 54,987 shares. Tal Ed Group (NYSE:XRS) was raised too.

Among 9 analysts covering Huntington Ingalls Industries (NYSE:HII), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. Huntington Ingalls Industries had 30 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Monday, July 17 by Cowen & Co. The stock has “Neutral” rating by Citigroup on Wednesday, March 1. The rating was maintained by Credit Suisse with “Neutral” on Thursday, November 9. The stock of Huntington Ingalls Industries, Inc. (NYSE:HII) earned “Hold” rating by Cowen & Co on Friday, May 5. The firm has “Hold” rating by Cowen & Co given on Tuesday, August 22. Cowen & Co initiated the stock with “Market Perform” rating in Thursday, October 1 report. The company was upgraded on Friday, November 6 by Wells Fargo. The firm has “Hold” rating by Cowen & Co given on Thursday, August 3. The firm has “Buy” rating by Guggenheim given on Wednesday, January 20. Wells Fargo downgraded the stock to “Market Perform” rating in Friday, August 5 report.

Investors sentiment decreased to 1.57 in 2017 Q3. Its down 0.02, from 1.59 in 2017Q2. It fall, as 17 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported. Granahan Investment Mngmt Inc Ma holds 465,090 shares. 3.93 million were accumulated by Vanguard Gru. Principal Fincl Gru stated it has 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 2,347 shares. Prelude Capital Mgmt Limited Com invested in 0% or 1,350 shares. New York State Common Retirement Fund invested in 113,230 shares. Ubs Asset Americas invested in 0% or 21,498 shares. 28,587 were accumulated by Parametric Port Assoc Ltd Company. Deerfield holds 653,000 shares. Bain Capital Public Equity Mngmt Ltd Liability Corp accumulated 203,791 shares. Massachusetts-based Ra Ltd Liability has invested 1.69% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). The Pennsylvania-based Federated Investors Pa has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Legal General Grp Inc Public Limited Liability Com reported 21,677 shares stake. Manufacturers Life Insurance The reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Pub Employees Retirement Association Of Colorado accumulated 25,992 shares.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.91 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Since September 1, 2017, it had 0 buys, and 8 sales for $1.88 million activity. Conner Edward R. also sold $92,436 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Tuesday, February 6. Herberts Curt A. III also sold $225,000 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares. The insider RINGO WILLIAM R sold 31,000 shares worth $445,597. Another trade for 11,520 shares valued at $237,159 was sold by Mento Steven J.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 2 by Jefferies. The rating was downgraded by Wedbush on Tuesday, November 1 to “Neutral”. The firm has “Buy” rating by Cowen & Co given on Friday, September 4. Piper Jaffray maintained it with “Hold” rating and $800 target in Thursday, August 10 report. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Wednesday, September 2 by Wedbush. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Sell” rating given on Tuesday, September 8 by Zacks. The firm earned “Hold” rating on Wednesday, November 15 by Wedbush. The stock has “Buy” rating by JP Morgan on Thursday, September 3. Piper Jaffray downgraded the shares of SGMO in report on Wednesday, October 19 to “Neutral” rating. The rating was reinitiated by Jefferies with “Buy” on Friday, October 23.

Leave a Reply

Your email address will not be published. Required fields are marked *